# US 2013/0095189 A1 · Composition and method of phytonutrients for metabolic programming effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0095189 A1
- Document ID: US20130095189A1
- Status: Published application
- Kind: A1
- Application number: 13/273,652
- Filed: 2011-10-14
- Published: 2013-04-18
- Earliest claimed: 2011-10-14
- Inventors: Zeina Jouni; Bryan Hanley; Aedin Cassidy
- Web page: https://patentgrep.com/patent/US20130095189A1

## CPC

- A23L 33/11: Plant sterols or derivatives thereof, e.g. phytosterols
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present disclosure relates methods of promoting phase II enzyme gene expression in a pediatric subject, comprising administering to the subject a nutritional composition comprising an effective amount of a phytonutrient. The disclosure also relates to methods of promoting phase II enzyme gene expression in a prenatal infant, comprising administering to a female pregnant with the prenatal infant an effective amount of a composition comprising phytonutrients. The disclosure further relates to a method of promoting phase II enzyme gene expression in a prenatal infant, comprising administering to a female pregnant with the prenatal infant an effective amount of a composition comprising phytonutrients.

## Claims

### Claim 1

A method of promoting phase II enzyme gene expression in a pediatric subject, comprising administering to the subject a nutritional composition comprising an effective amount of a phytonutrient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further promotes phase II enzyme protein expression.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method provides increased protection from xenobiotics when the pediatric subject becomes an adult.

### Claim 4 (depends on 1)

The method of claim 1, wherein the phase II enzyme is selected from the group consisting of glutathione transferase, UDP-glucuronosyltransferase, NAD(P)H:quinine oxireductase 1, sulfotransferases, N- & O-methyl transferases and a mixture thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pediatric subject is an infant ranging in age from about 0 to 12 months.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pediatric subject is a child ranging in age from about 1 to 6 years.

### Claim 7 (depends on 1)

The method of claim 1, comprising administering the nutritional composition to the pediatric subject prenatally, during infancy, and during childhood.

### Claim 8 (depends on 1)

The method of claim 1, wherein the phytonutrient is selected from the group consisting of a polyphenol, a carotenoid, an isothiocyanate, or a mixture thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the polyphenol is selected from the group consisting of flavonoids, flavonols, flavanols, flavanones, chalcones, flavonoids, isoflavonoids, anthocyanins, proanthocyanidins, cyanidins, and mixtures thereof.

### Claim 10 (depends on 8)

The method of claim 8, wherein the carotenoid is selected from the group consisting of lutein, zeaxanthin, astaxanthin, lycopene, beta-carotene, alpha-carotene, gamma-carotene, alpha-cryptoxanthin, beta-cryptoxanthin, and mixtures thereof.

### Claim 11 (depends on 8)

The method of claim 8, wherein the isothiocyanate is selected from the group consisting of sulforaphane, phenethylisothiocyanate, and mixtures thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the nutritional composition comprises about 50 to 1300 nmol/L of the phytonutrient.

### Claim 13 (depends on 1)

The method of claim 1, wherein the nutritional composition comprises about 500 to 2000 nmol/L of catechins.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition comprises about 50 to 400 nmol/L of quercetin.

### Claim 15 (depends on 1)

The method of claim 1, wherein the composition comprises about 0.01 to 70 mg/L of sulforaphane.

### Claim 16

A method of promoting phase II enzyme gene expression in an infant nursing from a lactating female, comprising administering to the lactating female a composition comprising an effective amount of a phytonutrient, and feeding the infant with breast milk from the lactating female.

### Claim at position 17

-19. (canceled)

### Claim 20

A method of promoting phase II enzyme gene expression in a prenatal infant, comprising administering to a female pregnant with the prenatal infant an effective amount of a composition comprising phytonutrients.

### Claim at position 19

21-23. (canceled)

### Claim 24

A milk-based nutritional composition, comprising a fat source, a carbohydrate source, a protein source and a phytonutrient source, wherein the composition is capable of promoting phase II enzyme gene expression in a pediatric subject.

### Claim at position 21

25-42. (canceled)

### Claim 43

A supplement for a pregnant or lactating female, comprising a phytonutrient source, wherein the supplement is capable of promoting phase II enzyme gene expression in:
a) a prenatal infant of the pregnant female, or
b) an infant nursing from the lactating female.

### Claim at position 23

44-46. (canceled)
